share_log

Ardelyx | 10-Q: Q3 2024 Earnings Report

Ardelyx | 10-Q: Q3 2024 Earnings Report

Ardelyx | 10-Q：2024财年三季报
美股SEC公告 ·  2024/11/01 04:12

Moomoo AI 已提取核心信息

Ardelyx reported robust Q3 2024 financial results, with total revenue reaching $98.2 million, up 74% from $56.4 million in Q3 2023. Product sales surged to $92.1 million, driven by IBSRELA sales of $40.6 million and XPHOZAH sales of $51.5 million. The company also recorded $5.3 million in product supply revenue and $0.8 million in non-cash royalty revenue.Operating expenses increased to $80.3 million from $41.3 million year-over-year, primarily due to expanded commercialization efforts for both IBSRELA and XPHOZAH. Research and development expenses rose to $15.3 million, while selling, general and administrative expenses grew to $65.0 million, reflecting increased investments in commercial infrastructure and personnel.The company ended the quarter with $190.4 million in cash, cash equivalents and short-term investments. Notable developments included signing a Commercial Supply Agreement with Hovione and securing a Fourth Amendment to its loan agreement with SLR Investment Corp, providing access to additional capital. The company believes its current financial position will fund operations for at least 12 months.
Ardelyx reported robust Q3 2024 financial results, with total revenue reaching $98.2 million, up 74% from $56.4 million in Q3 2023. Product sales surged to $92.1 million, driven by IBSRELA sales of $40.6 million and XPHOZAH sales of $51.5 million. The company also recorded $5.3 million in product supply revenue and $0.8 million in non-cash royalty revenue.Operating expenses increased to $80.3 million from $41.3 million year-over-year, primarily due to expanded commercialization efforts for both IBSRELA and XPHOZAH. Research and development expenses rose to $15.3 million, while selling, general and administrative expenses grew to $65.0 million, reflecting increased investments in commercial infrastructure and personnel.The company ended the quarter with $190.4 million in cash, cash equivalents and short-term investments. Notable developments included signing a Commercial Supply Agreement with Hovione and securing a Fourth Amendment to its loan agreement with SLR Investment Corp, providing access to additional capital. The company believes its current financial position will fund operations for at least 12 months.
Ardelyx公布了2024年第三季度强劲的财务业绩，总营业收入达到9820万元，较2023年第三季度的5640万元增长了74%。产品销售猛增至9210万元，其中IBSRELA的销售额为4060万元，XPHOZAH的销售额为5150万元。公司还记录了530万元的产品供应收入和80万元的非现金版税收入。营业费用从去年同期的4130万元上升至8030万元，这主要是由于对IBSRELA和XPHOZAH的市场推广力度加大。研发费用上升至1530万元，而销售、一般及行政费用增加至6500万元，反映了对商业制造行业和人员的投资增加。公司在本季度末手头现金、现金等价物和短期投资共计19040万元。重要进展包括与Hovione签署了商业供应协议，并与SLR Investment Corp达成了贷款协议的第四次修正，提供了额外资本的接入。公司相信其当前的财务状况能够支持运营至少12个月。
Ardelyx公布了2024年第三季度强劲的财务业绩，总营业收入达到9820万元，较2023年第三季度的5640万元增长了74%。产品销售猛增至9210万元，其中IBSRELA的销售额为4060万元，XPHOZAH的销售额为5150万元。公司还记录了530万元的产品供应收入和80万元的非现金版税收入。营业费用从去年同期的4130万元上升至8030万元，这主要是由于对IBSRELA和XPHOZAH的市场推广力度加大。研发费用上升至1530万元，而销售、一般及行政费用增加至6500万元，反映了对商业制造行业和人员的投资增加。公司在本季度末手头现金、现金等价物和短期投资共计19040万元。重要进展包括与Hovione签署了商业供应协议，并与SLR Investment Corp达成了贷款协议的第四次修正，提供了额外资本的接入。公司相信其当前的财务状况能够支持运营至少12个月。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    科技巨头财报季如火如荼，英伟达压轴会表现如何？
    星期四， $亚马逊 (AMZN.US)$ 股价在公司报告第四季度调整后每股收益为1.86美元，预估为每股1.50美元，营业收入为1877.9亿，预估为1873.2亿后下跌。该公司预测第一季度的营业收入数字低于华尔街的预期，预测本季度最多为1550亿，而分析师希望为1580亿。 星 展开
    亚马逊盈利预告：猜测开盘价，获取奖励！